First-or Second-line Therapy with Gefitinib Produces Equal Survival in Non-Small Cell Lung Cancer

Author

WU, Jenn-Yu¹ ; YU, Chong-Jen¹ ; YANG, Pan-Chyr¹ ; YANG, Chih-Hsin² ; WU, Shang-Gin¹ ; CHIU, Yueh-Hsia³ ; COW, Chien-Hung⁴ ; CHANG, Yeun-Chung⁵ ; HSU, Ya-Chieh¹ ; WEI, Pin-Fei⁶ ; SHIH, Jin-Yuan¹
[1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, Province of China
[2] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, Province of China
[3] Division of Biostatistics, Graduate Institute of Epidemiology and Center of Biostatistics Consultation, College of Public Health, National Taiwan University, Taipei, Taiwan, Province of China
[4] Division of Critical Care Medicine, Department of Emergency and Critical Care Medicine, Lo-Tung Poh-Ai Hospital, Yi-Lan, Taiwan, Province of China
[5] Department of Radiology, National Taiwan University Hospital, Taipei, Taiwan, Province of China
[6] Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan, Province of China

Source

American journal of respiratory and critical care medicine. 2008, Vol 178, Num 8, pp 847-853, 7 p ; ref : 40 ref

ISSN

1073-449X

Scientific domain

Pneumology

Publisher

American Lung Association, New York, NY

Publication country

United States

Document type

Article

Language

English

Author keyword

epidermal growth factor receptor gefitinib lung cancer mutations

Keyword (fr)

Anticancéreux Cancer du poumon Carcinome non petite cellule bronchopulmonaire Facteur croissance épiderme Géfitinib Mutation Réanimation Soin intensif Survie Traitement Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases Tumeur maligne

Keyword (en)

Antineoplastic agent Lung cancer non-small cell lung carcinoma Epidermal growth factor Gefitinib Mutation Resuscitation Intensive care Survival Treatment Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases Malignant tumor

Keyword (es)

Anticanceroso Cáncer del pulmón Carcinoma no pequeňa célula bronchopulmonar Factor de crecimiento epidérmico Gefitinib Mutación Reanimación Cuidado intensivo Sobrevivencia Tratamiento Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases Tumor maligno

Classification

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B27 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy / 002B27B Intensive care medicine

Pascal

002 Biological and medical sciences / 002B Medical sciences / 002B27 Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy / 002B27D Transfusions. Complications. Transfusion reactions. Cell and gene therapy / 002B27D01 Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis

Discipline

Anaesthesia. Reanimation. Transfusion. Cell therapy and gene therapy

Origin

Inist-CNRS

Database

PASCAL

INIST identifier

20778187

Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS